NZ710436A - Biospecific agents for bone - Google Patents

Biospecific agents for bone

Info

Publication number
NZ710436A
NZ710436A NZ710436A NZ71043614A NZ710436A NZ 710436 A NZ710436 A NZ 710436A NZ 710436 A NZ710436 A NZ 710436A NZ 71043614 A NZ71043614 A NZ 71043614A NZ 710436 A NZ710436 A NZ 710436A
Authority
NZ
New Zealand
Prior art keywords
bone
biospecific
mri
material core
contrast material
Prior art date
Application number
NZ710436A
Other languages
English (en)
Inventor
Matteo Santin
Steven Thomas Meikle
Lubinda Mbundi
Original Assignee
Orthopaedic Res Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthopaedic Res Uk filed Critical Orthopaedic Res Uk
Publication of NZ710436A publication Critical patent/NZ710436A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Signal Processing (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Theoretical Computer Science (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NZ710436A 2013-02-07 2014-01-31 Biospecific agents for bone NZ710436A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1302199.3A GB2510587B (en) 2013-02-07 2013-02-07 Biospecific agents for bone
PCT/GB2014/050265 WO2014122431A1 (en) 2013-02-07 2014-01-31 Biospecific agents for bone

Publications (1)

Publication Number Publication Date
NZ710436A true NZ710436A (en) 2020-07-31

Family

ID=47998779

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ710436A NZ710436A (en) 2013-02-07 2014-01-31 Biospecific agents for bone

Country Status (9)

Country Link
US (2) US20150367000A1 (enExample)
EP (1) EP2953682B1 (enExample)
JP (2) JP6400026B2 (enExample)
CN (1) CN105142729A (enExample)
CA (1) CA2898366C (enExample)
ES (1) ES2904260T3 (enExample)
GB (1) GB2510587B (enExample)
NZ (1) NZ710436A (enExample)
WO (1) WO2014122431A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3226905T3 (pl) 2014-02-27 2022-04-19 Synartro Ab Koniugaty kwasu hialuronowego z farmaceutycznie aktywnymi substancjami, sposoby i kompozycje
JP7156665B2 (ja) * 2017-06-13 2022-10-19 国立研究開発法人量子科学技術研究開発機構 医薬、並びにその製造方法
CN108187143A (zh) * 2018-02-09 2018-06-22 福州大学 一种兼具磁热效应和原位诱导成骨的多功能复合材料及其制备方法
CN109289119B (zh) * 2018-09-16 2022-05-17 华北理工大学 一种用于脊柱康复系统的磁性纳米粒子球混合物
US11944982B2 (en) 2019-06-05 2024-04-02 Battelle Memorial Institute Polymer-functionalized magnetic particle embodiments for solute separation, and devices and systems for using the same
CN111558041A (zh) * 2020-04-30 2020-08-21 浙江理工大学 羟基磷灰石包裹磁性载药纳米颗粒及其制备方法和在制备骨肉瘤光疗药物中的应用
WO2023041639A2 (fr) * 2021-09-15 2023-03-23 Centre National De La Recherche Scientifique Nanoparticules hybrides
CN117582485B (zh) * 2023-11-15 2024-06-07 湛江中心人民医院 方格星虫三肽在制备骨质疏松药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
WO2003072593A2 (en) * 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
CA2554755A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
CN101155549B (zh) * 2005-03-21 2011-11-16 加利福尼亚大学董事会 官能化磁性纳米颗粒及其使用方法
AU2012204100B2 (en) * 2005-03-21 2014-03-06 The Regents Of The University Of California Functionalized magnetic nanoparticles and methods of use thereof
ES2574810T3 (es) * 2005-09-28 2016-06-22 The Regents Of The University Of California Péptidos de unión a calcio
US20100028387A1 (en) * 2007-06-12 2010-02-04 Ganesan Balasundaram Biocompatible Coated Nanostructured Titanium Surfaces
US8063636B2 (en) * 2009-05-29 2011-11-22 The Invention Science Fund I, Llc Systems, devices, methods, and compositions including targeted ferromagnetic structures
US9316645B2 (en) * 2011-10-07 2016-04-19 Brown University Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging

Also Published As

Publication number Publication date
EP2953682B1 (en) 2021-10-13
EP2953682A1 (en) 2015-12-16
JP6400026B2 (ja) 2018-10-03
CA2898366C (en) 2021-05-04
GB2510587A (en) 2014-08-13
CA2898366A1 (en) 2014-08-14
GB201302199D0 (en) 2013-03-27
ES2904260T3 (es) 2022-04-04
CN105142729A (zh) 2015-12-09
JP2016509007A (ja) 2016-03-24
GB2510587B (en) 2020-05-20
US11464878B2 (en) 2022-10-11
US20150367000A1 (en) 2015-12-24
WO2014122431A1 (en) 2014-08-14
JP2018199693A (ja) 2018-12-20
JP6683773B2 (ja) 2020-04-22
US20200215207A1 (en) 2020-07-09
HK1217910A1 (zh) 2017-01-27

Similar Documents

Publication Publication Date Title
NZ710436A (en) Biospecific agents for bone
Pepin et al. Magnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications
WO2014160701A3 (en) Mri with repeated k-t -sub-sampling and artifact minimization allowing for free breathing abdominal mri
MX348558B (es) Metodo implementado por ordenador para evaluar redes vasculares a partir de imagenes medicas y usos del mismo.
Srivatsan et al. Recent advances in nanoparticle-based nuclear imaging of cancers
JP2012531229A5 (enExample)
IL242422B (en) A pharmaceutical preparation containing a therapeutic agent based on modified hemoglobin for targeted cancer treatment and diagnostic imaging
WO2012095797A3 (en) 4d contrast enhanced computed tomography (ct)
GB201020077D0 (en) Correlating planar to tomograph data
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
GB2548025A (en) Systems and methods for anatomy-based registration of medical images acquired with different imaging modalities
SG10201804772UA (en) Method of imaging living tissue
WO2018174721A3 (en) Indicator fluids, systems, and methods for assessing movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity of a human
Huhndorf et al. Systematic brain tumor conductivity study with optimized EPT sequence and reconstruction algorithm
GB201121914D0 (en) Method for patient selection
WO2013110013A8 (en) Methods and compositions for objectively characterizing medical images
WO2015017506A3 (en) Nanoparticle diagnostic and methods for treating disease
Calabria et al. A case of intracranial meningioma detected by 18F-choline PET/CT and examined by PET/MRI fusion imaging
Tsai et al. Xanthogranuloma of sellar region: a case report with diagnostic imaging findings, treatment response and literature review
EP2844776A4 (en) CANCER BLOOD TEST USING INSULATED BC200 RNA FROM PERIPHERAL BLOOD FOR THE DIAGNOSIS AND TREATMENT OF INVASIVE BREAST CANCER
RU2008106162A (ru) Способ диагностики глиом и внутримозговых гематом больших полушарий головного мозга
Pande Incidental findings of susuk in orthopaedic patients
Sardan et al. Bioactive peptide functionalized superparamagnetic iron oxide nanoparticles (SPIONs) for targeted imaging with MRI
UA65234U (ru) Способ определения объема или необходимости дальнейшего оперативного вмешательства при опухолевом процессе в щитовидной железе
GB201315423D0 (en) Paramagnetic metal labelled monoclonal antibody against Propionbacterium acnes for in vivo diagnostic using MRI or CT scan

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2022 BY DENNEMEYER + CO.

Effective date: 20210118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2024 BY DENNEMEYER + CO. SARL

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2025 BY DENNEMEYER + CO. S.A R.L.

Effective date: 20240129

LAPS Patent lapsed